-
Coronavirus for patients: Plan your blood thinner medication refills
Beth Waldron, MA writes….For patients on life-saving therapies like blood thinners (anticoagulants) having several weeks supply of medication on hand during the coronavirus outbreak is important not only to reduce the need to be out in public, but to ensure you have everything you need already at home if you do get sick. However, getting…
-
Antiphospholipid Syndrome: Can the New Oral Anticoagulants Be Used?
Stephan Moll, MD and Damon Houghton, MD write … In patients with antiphospholipid syndrome (APS) who require anticoagulation for the treatment of DVT or PE, warfarin or a low molecular weight heparin have traditionally been used. A question that comes up is whether one of the new oral anticoagulants (DOACs) can be effectively and safely…
-
Heavier Menstrual Bleeding on Xarelto?
Stephan Moll, MD writes… Interesting and noteworthy observations published in the last 2 weeks: Heavy menstrual bleeding appears to occur more commonly with Xarelto® than with warfarin [ref 1] and may be also more common with Xarelto® than with Eliquis® [ref 2].
-
Eliquis (Apixaban) News – Plus Update On The Big Four New Oral Anticoagulants
There is a lot of appropriate interest and excitement today about one of the four new blood thinners in development – Apixaban (Eliquis). Data from the large atrial fibrillation trial called ARISTOTLE were published today and show that the drug is more effective and safer than warfarin in patients with atrial fibrillation [ref 1]. This…
-
Eliquis (Apixaban) – Good News
Eliquis (Apixaban) is one of the 4 promising new oral “blood thinners” that (a) do not require monitoring of its “blood thinning” (anticoagulant) effect, i.e. do not require INR monitoring, and (b) do not interfere with vitamin K in the diet, i.e. patients can eat what they want.
-
Apixaban (Eliquis): Another New Oral “Blood Thinner”
Good news. Another one of the new oral “blood thinners” in development, Apixaban (Eliquis®), has moved forward. On May 23rd, 2011 the European Medicines Agency (EMA) approved Eliquis® for marketing in the 27 countries of the European Community for DVT prevention after orthopedic surgery (hip and knee replacement). In the U.S., Eliquis® is not yet FDA approved, and still…
